Incidence of medication-related harm in older adults following hospital discharge: a systematic review by Parekh, Nikesh et al.
Incidence of medication­related harm in older adults following 
hospital discharge: a systematic review
Article  (Accepted Version)
http://sro.sussex.ac.uk
Parekh, Nikesh, Ali, Khalid, Page, Amy, Roper, Tom and Rajkumar, Chakravarthi (2018) 
Incidence of medication-related harm in older adults following hospital discharge: a systematic 
review. Journal of the American Geriatrics Society, 66 (9). pp. 1812-1822. ISSN 1532-5415 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/74837/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
 1
Incidence of medication-related harm in older adults following hospital discharge: A 1 




clinical research fellow in geriatrics, Khalid Ali MD1,2, senior lecturer 4 
in geriatrics, Amy Page PhD3, clinical pharmacy research fellow, Tom Roper BA(Hons)2, 5 
clinical librarian, Chakravarthi Rajkumar PhD1,2, chair in geriatric and stroke medicine  6 
 7 
1 Academic department of Geriatric Medicine, Brighton and Sussex Medical School, 8 
Brighton, Sussex, UK 9 
2 Department of Elderly Medicine, Brighton and Sussex University Hospitals NHS Trust, 10 
Sussex, UK 11 
3 School of medicine and pharmacology, University of Western Australia, Australia 12 
 13 
 14 
Corresponding author: Professor C Rajkumar, Chair in Geriatric and Stroke Medicine, 15 
Brighton and Sussex Medical School, Audrey Emerton Building, Eastern Road, Brighton, 16 
Sussex, UK BN2 5BE  17 
Tel. +44(0)1273523360 18 
c.rajkumar@bsms.ac.uk   19 
 20 
Abstract Word Count: 288 21 
Main Text Word Count: 3500 22 
Tables: 4 23 









Page 1 of 31 Journal of the American Geriatrics Society
 2
Abstract 33 
Objectives To determine the incidence, severity, preventability and risk factors for 34 
medication-related harm (MRH) in community-dwelling older adults following hospital 35 
discharge.  36 
Design Systematic review 37 
Setting A search of Medline, EMBASE, CINAHL, and the Cochrane Library was undertaken 38 
without time restrictions 39 
Participants Older adults (average age ≥65 years) participating in observational studies 40 
investigating adverse drug reactions (ADR) or adverse drug events (ADE) post-discharge 41 
within a defined follow-up period 42 
Measurements The abstracts of all articles were initially screened by one author to exclude 43 
obviously irrelevant articles.  The remaining articles were independently screened by two 44 
authors for inclusion.  Data extraction, including study characteristics, MRH incidence and 45 
risk factors, and, critical appraisal was performed by two authors independently, and 46 
verified by a third reviewer.  Disagreements were resolved through discussion. 47 
Results Out of 584 potentially relevant articles, eight studies met our inclusion criteria; five 48 
North American and three European.  Most of the included studies were of moderate 49 
quality.  There was a wide range in MRH incidence, from 0.4% to 51.2% of patients, and 35% 50 
to 59% of MRH was preventable.  The MRH incidence within 30 days post-discharge ranges 51 
from 167 to 500 events per 1000 patients discharged (17-51% of patients).  Substantial 52 
methodological heterogeneity exists across multiple domains of the studies, including ADR 53 
and ADE definitions, characteristics of recruited populations, the follow-up duration post-54 
discharge, and data collection.  55 
Conclusions Medication-related harm is common following hospital discharge in older 56 
adults.  However, a clear understanding of the epidemiology is hampered by methodological 57 
inconsistencies between studies and a paucity of data on risk factors.  There is need for 58 
international consensus on conducting and reporting MRH studies.  Data from large, 59 
multicentre studies examining a range of biopsychosocial risk factors could add insight to 60 
this important area of patient safety. 61 
 62 
Key Words Systematic review, older adults, medication harm, hospital discharge, 63 
epidemiology 64 




Reducing severe, avoidable medication-related harm (MRH) by 50% over the next five years 67 
is the World Health Organisation’s third global patient safety challenge 1.  The MRH 68 
experienced by patients is often described in terms of (1) adverse drug reactions (ADR), 69 
where patients experience a noxious and unintended reaction caused by a medicine at 70 
appropriate dosage, or, (2) adverse drug events (ADE) which includes an ADR or an injury 71 
related to medicine use at inappropriate dosage (e.g. a medical error) 2–7.  In this paper, ADR 72 
and ADE is discussed as ‘medication-related harm’ (MRH), in accordance with recent World 73 
Health Organisation (WHO) terminology1.    74 
Older adults (≥ 65 years) are a particularly high-risk population for MRH due to 75 
polypharmacy 8 and age-related pharmacokinetic and pharmacodynamics changes. 9 76 
Approximately 10% of hospital admissions of older adults are attributable to MRH 10, and 77 
the incidence of MRH is increasing in Europe and the United States (US) 11–14; between 78 
2005/6 to 2013/14 the rate of US emergency department visits for MRH almost doubled 79 
from 5.2 to 9.7 visits per 1000 older adults. Excess healthcare cost in the US due to a 80 
preventable MRH event to a community-dwelling older adult has been estimated at 81 
$2000.15 82 
 83 
Reducing MRH during transitions of care is a priority area in the WHO’s global challenge16.  84 
Patients and carers describe the transition period around hospital discharge as posing a 85 
unique, high risk situation for the occurrence of MRH17–19. During this period, patient 86 
deconditioning from hospitalisation alongside ongoing recovery from illness 20 is 87 
compounded with frequent confusion and inaccuracies in medicines management.  88 
Medication discrepancies affect up to one in two older patients around hospital discharge 89 
21, and can be compounded with administrative difficulties receiving medicines and poor 90 
patient education of medicines use 22.  Coordination following hospital discharge between 91 
secondary care, primary care, and patients and carers, is commonly inadequate.  Based on 92 
four studies from the US and Australia, a recent systematic review found that 5%-38% of 93 
discharge summaries are never received by primary care physicians 23.  The quality of 94 
information communicated is also problematic.  For instance, the same review found that 95 
40% of discharge summaries did not provide diagnostic test results, 75% no information on 96 
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pending tests, 22% lacked information on discharge medications and 58% did not 97 
communicate follow-up plans.  98 
A review of medication problems experienced by older adults around hospital discharge was 99 
conducted almost a decade ago24.  Fourteen studies of medication problems in community 100 
and care home settings, including medication discrepancies, education, non-adherence, 101 
drug interactions and MRH, were identified.  The authors could not estimate the magnitude 102 
of the problem due to study heterogeneity.  In the meantime, despite no systematic 103 
quantification of the problem, there have been numerous interventional studies to reduce 104 
MRH in the post-discharge period 25,26.  In view of this we conducted a systematic review to 105 
specifically investigate the epidemiology of MRH, in contrast to all medication problems 106 
which may or may not manifest in patient harm.  Our aim was to determine the incidence, 107 
severity, preventability and risk factors for MRH in community-dwelling older adults post-108 




We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses  113 
(PRISMA) guidance (Table S1) in conjunction with the Joanna Briggs Institute methodological 114 
guidance for systematic reviews of observational epidemiological studies
27
.  Our primary 115 
objective was to provide a synthesis of the epidemiological data on MRH in community-116 
dwelling older adults following hospital discharge.  117 
 118 
 119 
Search strategy 120 
Two authors (NP and TR) initially conducted an electronic search of Medline, EMBASE, 121 
CINAHL, and the Cochrane Library, from their inception to June 2016 without restrictions.  122 
We re-ran this search in June 2017 looking for any new studies.  The search strategy was 123 
designed in Medline (using the Healthcare Databases Advanced Search from the National 124 
Institute of Health and Care Excellence) using a combination of key words and Medical 125 
Subject Headings (MeSH) (Table S2).  We subsequently adapted this search strategy for 126 
EMBASE and CINAHL.  Key concepts in the search strategy were ‘adverse drug reaction’, 127 
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‘elderly’ and ‘hospital discharge’. For each of these concepts, synonyms, related terms and 128 
controlled vocabulary terms were selected and combined using Boolean and proximity 129 
operators, and truncation, to ensure alternative forms were retrieved.  In addition to this, 130 
reference lists of relevant articles were scanned to identify any articles not found in the 131 
electronic search.  We also consulted the studies in a review published in 2010 on a similar 132 
theme24, conducted forward citation searches on this prior review and on studies that we 133 
identified for inclusion, and successfully corresponded with investigators of four included 134 
studies to ensure we did not miss any articles.         135 
 136 
Selection criteria 137 
We considered all published observational studies that evaluated MRH (ADR or ADE) to 138 
community-dwelling older adults (average age ≥65 years) within a defined follow-up period 139 
after hospital discharge.  We included studies where the incidence or prevalence of MRH 140 
was reported or could be calculated.  Given our objective was to establish the extent of 141 
MRH is the general older population discharged from hospital, we had the following 142 
exclusion criteria; (1) studies investigating only re-hospitalized patients, (2) studies only 143 
investigating patients with a specific disease, condition, or harms of one particular medicine, 144 
(3) studies of institutionalized patients.   145 
 146 
Outcomes 147 
Our primary outcome of interest was the incidence of MRH post-discharge.  Secondary 148 
outcomes included the proportion of serious events, preventable events, and associated risk 149 
factors. 150 
 151 
Study selection 152 
The titles and abstracts of identified articles were screened by one author (NP) to exclude 153 
obviously irrelevant articles (n=338).  The remaining papers (n=215) were independently 154 
screened by two authors (NP and AP), excluding those identified as reviews, interventional 155 
studies, conference proceedings, research letters and protocol papers, articles related to a 156 
specific medicine or condition, or, not investigating the period post-hospital discharge.  Full-157 
text articles of potentially eligible titles and abstracts were independently reviewed by the 158 
same two authors and selected according to inclusion criteria.  These studies were then 159 
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reviewed by a third author (KA) to confirm their eligibility for inclusion.  Any disagreement 160 
was resolved through discussion. 161 
 162 
Data extraction 163 
Data extraction was performed independently by two reviewers (NP and AP) onto a 164 
standard data collection form (Table S3), and verified by a third reviewer (KA). We extracted 165 
the following data from included articles: study year and country, study design, discharge 166 
setting, duration of follow-up, methods used for data collection and causality assessment, 167 
ADE and ADR incidence or prevalence, severity, preventability, and, associated risk factors. 168 
 169 
Quality assessment 170 
Two authors (NP and AP) independently assessed the quality of included studies using the 171 
Joanna Briggs Institute critical appraisal tool for prevalence studies 27.  The nine domains in 172 
this tool address sampling bias (target population, sampling, sample size, description of 173 
participants and setting), coverage bias (coverage of identified sample), measurement bias 174 
(methods to identify outcome, reliability in outcome measurement, appropriate statistical 175 
analysis), and, non-response bias (response rate).  Where any disagreements arose, these 176 
were resolved through discussion.  A risk of bias figure was completed for included studies 177 
using RevMan Version 5.3.    178 
 179 
Data synthesis 180 
We report the incidence proportions of MRH stated in the included studies.  In studies 181 
where this was not clearly stated, we calculated the incidence proportion from the available 182 
data (number of persons that developed MRH / total population at risk).  Where the 183 
number of events within the population was stated, we additionally calculated the incidence 184 
of events per 1000 discharges.  We have not reported incidence rates (where follow-up time 185 
is incorporated into the denominator) as this would be misleading, given that the risk of 186 
MRH following hospital discharge is not constant over time.  Data was extracted on the 187 
medicine classes commonly implicated in MRH.  If this was reported in an alternative format 188 
e.g. mixture of medicine classes and specific medicines themselves, we categorised the 189 
medicines using the WHO Anatomical Therapeutics Coding system
28
.    190 
 191 




Study Selection 194 
We identified 584 individual records from our search strategy, out of which we read 31 195 
articles in full as they were deemed relevant based on their title and abstract.  From this we 196 
excluded 24 articles as they did not meet all the inclusion criteria, and one additional study 197 
was identified from a reference list of an article.  Therefore, eight observational studies met 198 
our inclusion criteria (Figure 1).   199 
 200 
Study Characteristics  201 
Study characteristics are outlined in Tables 1 and 2.  Five studies were conducted in North 202 
America29–33, and three studies in Europe (Netherlands34, Croatia35 and France36).  All the 203 
identified studies were cohort studies (prospective, n=529–31,34,35, retrospective, n=232,33), 204 
and one which was a prospective population-based study 36.  The number of participants 205 
included in the studies ranged from 209 to 7540, and the mean age of patients 67.7 to 80.0 206 
years.   207 
 208 
Participant recruitment and follow-up  209 
The recruitment setting varied between studies, with most studies recruiting from general 210 
medical wards, however others specified inclusion of patients also from surgical wards
30
 and 211 
all wards
36
. Most studies excluded patients discharged to a nursing home, those with a 212 
terminal illness and patients admitted to psychiatric units.  However, one study exclusively 213 
recruited patients discharged to receive nursing care at home 
31
.  Three studies excluded 214 
patients with dementia; one excluded all patients with dementia
35
, one excluded those with 215 
severe dementia
30
 and another excluded those with dementia and no home carer 
31
.  216 
Objective criteria for the diagnosis and severity of dementia were not reported. 217 
The period of follow-up post-hospital discharge was one month in five studies
29,31,33,35,36
, 218 
whilst the shortest follow-up was two weeks 
34
 and the longest one year 
30
.  Half of the 219 
studies recruited patients from more than one hospital 
30,33,34,36
.  A nationwide study of 220 
post-discharge ADR from France recruited patients referred to hospital for all causes by 221 
their GP, and then followed up only the subset of patients that re-consulted their GP within 222 
30 days of discharge 
36
.   223 
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 224 
Definition of MRH 225 
Definitions of MRH varied between studies, and two studies did not report an explicit 226 
definition29,31.  Two studies used a World Health Organisation definition of ADR 35,36, and 227 
one used a modification of this to include harm from therapy discontinuation36 .  Another 228 
study classified a range of medication problems under ADR including ‘unsafe drug for 229 
patient, allergic reaction, contraindication present, incorrect administration, clinically 230 
relevant drug interaction, undesirable effect’ 33.  Two studies reporting ADE had a very 231 
similar definition29,32, however, one of these included harms from patient non-adherence.32 232 
 233 
Data collection and MRH causality assessment 234 
Data collection was primarily through medical chart reviews 32,33 and in some cases also 235 
patient interview; patients were interviewed by telephone 29,30 or in-person 31,34,36 , and in 236 
one study the interview was combined with a physical examination of patients35. 237 
Data was collected by a range of health professionals, including community-based pharmacy 238 
technicians 34, to clinical pharmacists 32 and GP 36 to physicians with expertise in clinical 239 
pharmacology35.  Only some studies reported use of a tool to attribute causality to a 240 
medicine for a particular harm, and this included the validated Naranjo algorithm 30,31,35 , 241 
and an algorithm designed by French experts in pharmacovigilance 
36
.  242 
 243 
Methodological Quality  244 
The results of our critical appraisal of the included studies can be seen in Figure S1.  Overall, 245 
the literature base was of moderate quality.  Our assessment found that in five out of eight 246 
studies the sample frame (i.e. recruited cohorts to investigate the target population) was 247 
associated with a high risk of bias
30,31,33,34,36
.  Quality indices that we assessed to have low 248 
risk of bias included the sample size, sampling method, and the methods used to identify 249 
MRH.  250 
 251 
Incidence of MRH  252 
The incidence proportion of MRH ranged from 0.4% patients within 30 days of discharge 
36
, 253 
in a French study of ADR presenting to primary care post-discharge, to 51.2% over a two-254 
week period post-discharge 
34
 in a Dutch study reporting ‘side-effects’ to medicines (Table 255 
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3).  The incidence of MRH events ranged from 4.0 per 1000 patients over 30 days to 615.1 256 
per 1000 patients over one year of follow-up 30. The follow-up period in most studies (n=5, 257 
62.5%) was 30 days29,31,33,35,36.  The MRH incidence within 30 days post-discharge ranged 258 
from 167 to 500 events per 1000 patients (17-51% of discharged patients)29,31,33,35, excluding 259 
the very low MRH incidence reported by Letrilliart et al (2001) where only patients 260 
consulting their GP were followed-up. 36  The substantial methodological variation between 261 
studies precludes reliable meta-analysis of the MRH incidence 27. 262 
 263 
Severity, preventability and risk factors   264 
Severity of MRH was determined in four studies30,32,35,36.  Two studies used the same criteria 265 
to define serious MRH35,36; death, life-threatening, hospitalisation or disability.  The 266 
proportion of total MRH judged ‘serious’ ranged from 6.9%35 to 60% 36 (Table 3).  267 
Preventability of MRH was reported in four studies with variable definitions, and ranged 268 
from 35% to 59% of MRH30,32,35,36 (Table 3). 269 
 270 
Cardiovascular medicines were the most commonly prescribed drugs at hospital 271 
discharge.31,35 They were implicated in the largest proportion of MRH, associated with 272 
18.8% to 55.7% of events30–33,35,36.  Anticoagulants were also a commonly implicated drug 273 
class, associated with up to 20% of events 
36
.  Four studies examined the association of risk 274 
factors with MRH
30,31,35,36
, and three of these studies performed multivariable analysis to 275 
identify independent predictors
30,31,35
(Table 4).  Increasing number of medicines
30,35







, lower score on Mini-Mental State 277 
Examination for impaired cognition 
31
 and female gender
31
 were independent risk factors 278 




To our knowledge, this is the first systematic review to describe the epidemiology of 283 
medication-related harm in community-dwelling older adults after hospital discharge.  We 284 
included eight studies reporting a wide range in the incidence of MRH, from 0.4% to 51.2% 285 
of patients.  We found substantial methodological heterogeneity between studies, including 286 
(1) outcome definitions i.e. WHO definition of ADR to no reported definition, (2) the 287 
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population cohort recruited i.e. patients with polypharmacy to patients requiring 288 
community nursing care, (3) the follow-up period i.e. from 14 days to 365 days, and, (4) the 289 
data collection methods i.e. using solely medical records to including patient interviews, and 290 
physical examination.  Leendertse et al’s review in 2010 of medication-related 291 
hospitalisations similarly demonstrated major variations in study characteristics resulting in 292 
a prevalence range of 0.1% to 54% between identified studies 37.  Our review indicates that 293 
a lack of consensus on conducting and reporting MRH research continues to hamper a clear 294 
understanding of the burden of MRH.  295 
 296 
Our results show that MRH is experienced by a considerable proportion of older adults 297 
within 30 days post- discharge.  The one-month incidence ranges from 167 to 500 events 298 
per 1000 patients (17-51% of patients).  This does not include one study that reported an 299 
outlying low incidence of MRH (0.4% patients), where only patients that consulted their GP 300 
post-discharge were followed-up.36  This study excluded MRH that resulted in the use of 301 
other health services e.g. the emergency department, or self-managed at home, and 302 
therefore underreported the magnitude of MRH.  Ahmad et al (2014) found that half of the 303 
discharged patients in their study experienced MRH within two weeks of discharge 34.  This 304 
was a high incidence relative to other studies and is likely to reflect the particularly high-risk 305 
cohort of polypharmacy patients that were recruited.   306 
 307 
Between 35% and 59% of MRH was preventable in the included studies, and this builds on a 308 
previous systematic review of MRH in the community (not post-discharge) in all age groups 309 
which reported 11-27.5% as preventable 
38
. Given the high risk around hospital discharge of 310 
medication discrepancies, 
39,40
 poor communication to patients of medication changes and 311 
possible adverse effects, 
17,36,41
 and deficiencies in information transfer to primary care, 
23
 312 
the higher proportion of preventable MRH that we report is not a surprise.   313 
 314 
None of the included studies considered the financial costs of MRH to healthcare systems.  315 
Reducing preventable MRH post-discharge may be an opportunity for financial savings 316 
within healthcare systems.  An economic analysis of the direct costs from healthcare 317 
utilisation attributable to post-discharge MRH within a large, multicentre prospective study 318 
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would be a starting point.  Currently data on MRH costs are predominantly based on 319 
hospital inpatients42,43 320 
 321 
Our findings highlight the crucial need for consensus in defining MRH, collecting MRH data, 322 
ascribing causality and reporting findings.  There are multiple definitions for ADR and 323 
ADE,3,5–7 and these can be contradictory. For example, the WHO definition of ADR stipulates 324 
‘a response to a medicine which is noxious and unintended, and which occurs at doses 325 
normally used in man’ 7(thereby excluding error), whereas the definition by Edwards and 326 
Aronson (2000) includes ADR related to alternative doses that might have arisen by error5. 327 
The common exclusion of MRH due to non-adherence and medical error in ADR studies 328 
does not reflect the reality of patient experience19 or clinical practice4.  We recommend that 329 
future studies identify harm due to non-adherence and medical error alongside ADRs, 330 
reporting these separately and collectively under the terminology of ‘medication-related 331 
harm’.  This would align with the WHO’s global medication safety initiative 1.  332 
 333 
Data collection for MRH studies is more accurate when multiple sources are used6,44.  334 
Studies that rely solely on medical chart review are likely to underestimate MRH events44; 335 
patient surveys or interviews are a valuable contribution to MRH data45,46 and should be 336 
routinely captured to generate more robust evidence
47
.  Only one study included a medical 337 
examination looking for physical signs of MRH, conducted by a physician with clinical 338 
pharmacology training.
35
 The authors did not report the proportion of MRH that was 339 
identified with this unique approach relative to chart reviews and patient reports.  However, 340 
several patients experiencing statin-induced myopathy and corticosteroid-induced Cushing’s 341 
syndrome were identified that could have been missed without a clinical examination.  The 342 
value of the examination will of course depend upon the education and training of the 343 
physician conducting it.  344 
 345 
Whilst no gold standard exists for ascribing causality when assessing MRH
48
, combining an 346 
algorithmic approach (e.g. Naranjo
49
) and expert opinion from multiple reviewers is 347 
comprehensive and may improve the accuracy of causality judgements
50
. Similar to the 348 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
51
 formulated by 349 
the International Society for Pharmacoeconomics and Outcomes Research, we recommend 350 
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an international, multidisciplinary task force (including academia, clinicians, pharmaceutical 351 
industry, regulatory authorities, and patient and carer representation52) to formulate best 352 
practice guidance for investigating and reporting MRH.  A Delphi Panel could be organised 353 
online, requiring minimal financial support, and is a validated methodology to achieve 354 
expert consensus53.     355 
   356 
 357 
There is no established time-frame defining the heightened risk of adverse events in the 358 
post-discharge period.  Five studies (63%) in our review followed-up participants for 30 359 
days.  While arbitrary, this is consistent with the ‘post-hospital syndrome’ describing a 30-360 
day period of heightened vulnerability from ongoing illness recovery and the physiological 361 
stresses of hospitalisation, including sleep deprivation, poor nutrition and deconditioning 20.  362 
Kanaan et al (2013) investigated a 45 day post-discharge period and found the vast majority 363 
of MRH takes place within 30 days 32, whilst Hanlon et al (2006) conducted a one-year 364 
follow-up and showed that MRH occurred predominantly in the first three months 30.  Some 365 
MRH manifests over an extended time-frame e.g. immunosuppression-related sepsis or 366 
osteoporotic fracture from extended prednisone use in temporal arteritis.  These cases of 367 
MRH would likely be missed in a limited follow-up of weeks (or even months), which makes 368 
it particularly challenging to propose a specific follow-up period. 369 
 370 
There were specific medication-related features that were associated with an increased risk 371 
of MRH in more than one study.  Increasing number of medicines, a well-established risk 372 
factor for MRH in the inpatient setting 
54
, was an independent predictor of post-discharge 373 
MRH in two included studies 
30,35
.     Our results also highlighted warfarin as a significant 374 
risk-factor
30,35
, however, the most recent included study by Westberg et al (2017) did not 375 
find that anticoagulants were a particularly frequent class of drug implicated in MRH
33
.  This 376 
could reflect changing prescribing patterns of anticoagulant use from vitamin-K antagonists 377 
to direct oral anticoagulants, and indications that some direct oral anticoagulants have an 378 
improved safety profile over warfarin 
55
.  Only the study by Gray et al (1999) explored the 379 
influence of psychosocial factors on the risk of MRH, and found that reducing cognition as 380 
measured on mini-mental state examination was significant
31
.  None of the studies 381 
investigated the role of low health literacy, which is increasingly recognised as a potentially 382 
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modifiable determinant of MRH56.   The influence of other important variables such as 383 
frailty, carer support, and socioeconomic status are yet to be explored, and could prove 384 
fruitful to increasing our understanding of the pathways underlying MRH.  385 
 386 
Our review has several limitations.  Although we performed a comprehensive literature 387 
search, we could not identify unpublished studies.  The heterogeneity of the identified 388 
studies precluded a meta-analysis to estimate the incidence of MRH, our primary outcome 389 
of interest.  Several outcomes of interest, including the severity and preventability of MRH 390 
were reported in only a proportion of included studies and mostly not improved through 391 
contact with original investigators.  Many studies excluded patients with dementia and 392 
patients discharged from psychiatric wards.  Given the high number of medicines used in 393 
these patients, it is important that future studies are designed to include such patient 394 




Medication-related harm is common in older adults following hospital discharge.  However, 399 
a clear understanding of its epidemiology is hampered by methodological inconsistencies 400 
between studies.  There is a need for further prospective epidemiological research on this 401 
topic to identify key risk factors, and international consensus on conducting and reporting 402 
studies investigating MRH. 403 
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Table 1. Characteristics of included studies 
Study 
(Year) 









in years  















67.7+/-13.8  Patients had been pre-selected 
based on risk profile as requiring 
medication review in the 
community. Key exclusions: 











14 340 76 (range 60-95) Key exclusions: Patients using 
less than five long-term 
medicines; psychiatry or 






One hospital, one 
general medical 
ward 
30 209 74 (range 65-89) Key exclusions: impaired 
cognition, terminal illness, 













78.8 +/-7.1 Key exclusions: Psychiatric 







affairs hospitals.  
Medical or 
surgical wards. 




years, 46.4% 75 
years or over 
Key exclusions: nursing home, 
previously had geriatric specialist 
input in community or hospital, 
disabling or terminal disease, 
severe dementia, unable to 






















69 (range not 
reported) 
Patients referred to hospital by 
participating general practices 
and then re-consulted within 30 
days of hospital discharge. Key 








30 312 80 +/-7.3 Patients receiving home nursing 
care.  Key exclusions:  terminally 
ill, recent MI or CVA, dementia 
without caregiver at home, non-
ambulatory 
Definitions: Medication-related harm (MRH), Adverse Drug Reaction (ADR), Adverse Drug Event (ADE), General Practitioner (GP), Standard Deviation 
(SD), Interquartile range (IQR) 
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Table 2: MRH assessment in the included studies 
Study 
(Year) 
Study aim Type 
of 
MRH 




To describe the 
number, 
classification, and 
severity of drug 
therapy problems in 
patients 
transitioning from 
hospital to home 
ADR ADR comprised unsafe drug for 
patient, allergic reaction, 
contraindication, incorrect 
administration, clinically relevant 
drug interaction, undesirable effect 
Not reported Pharmacist initially documents 
drug-related problem during 
community medication review 
and then 3 clinician investigators 
(one physician, one clinical 
pharmacist, one resident 
pharmacist) evaluated the record 
to attribute clinical significance 
and likelihood of harm. 
Ahmad 
(2014) 
To investigate the 
occurrence of MRP 
in discharged 
patients 
ADE Not reported  Two clinical 
pharmacologists 
reviewed information 




systems to verify ADE 
Semi-structured patient interview 
by pharmacist technicians.  
Marusic 
(2014) 
To evaluate the 
incidence of ADRs in 
elderly patients 
following discharge 
from an internal 
medicine clinic 
ADR ADR is one that is noxious, 
unintended and occurs at a dose 
normally used in humans 
Independent physician 
review using Naranjo 
Algorithm. 
Follow-up interview and medical 
examination 30 days post-
discharge where physician with 







period in older 
adults 
ADE ADE defined as an injury resulting 
from a drug, rather than an 
underlying disease. An ADE can be 
related to an error or an ADR without 
an error. 
Physician-reviewers 
considered the sequential 
relation of drug exposure 
and event, and whether 
event was a known 
potential side-effect 
Primary and secondary care 




To examine the 
incidence of ADRs in 
frail elderly persons 
after hospital 
discharge 
ADR ADR is one that is noxious, 
unintended and occurs at a dose 
normally used in humans* 
Blinded geriatric 
physician/pharmacist 
reviewer pairs evaluated 
the ADR narratives 
prepared by clinical 
pharmacists using the 
Naranjo algorithm.  
Chart reviews by research nurse 
and telephone interview by 
research pharmacist for patient 
self-report of ADR. Pharmacists 




To determine the 
risk, severity and 
type of adverse 
events after 
discharge 
ADE ADE are the subset of adverse events 
caused by medications -  adverse 
events are adverse outcomes caused 
by medical care as opposed to the 
underlying disease process* 
Two physicians reviewed 
each outcome and 
determined probability of 
causality by clinical 
judgement 
Telephone interview with patient 
by nurse or physician and chart 




To estimate the 
incidence of post-
discharge ADR 
detected in primary 
care 
 
ADR ADR is noxious, unintended and 
occurs at a dose normally used in 
humans, but also includes harm 
occurring from discontinuation of a 
necessary drug during hospital stay 
Combination of medical 
literature, physician 
expert judgement and 
published French 
algorithm  
Teleinformatic data transfer from 
GP to central information centre 
based on a standardised protocol 
Gray 
(1999) 
To describe the 
incidence of ADEs 





ADE Not reported Naranjo algorithm  Semi-structured patient interview 
by trained interviewers 
Abbreviations: Medication-related harm (MRH), Adverse Drug Reaction (ADR), Adverse Drug Event (ADE), General Practitioner (GP). *Definitions 
retrieved from contact with original investigators 
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Table 3. Incidence, preventability, and, severity of MRH  
Study 
(Year) 
Incidence of MRH 
(events per 1000 
patients discharged) 
Incidence of MRH in 
study population, % 
(follow-up duration) 
MRH Preventable, % (definition) MRH Serious, % (definition) 
Westberg 
(2017) 




500 51.2 (14 days) Not reported Not reported 
Marusic 
(2014) 
345 30.1 (30 days) 51.4  
(errors that could have been 




hospitalisation or disability) 
Kanaan 
(2013) 
242 18.7 (45 days) 35 
(due to error and preventable by 






615 33 (365 days) 37.6 
(prescribing, monitoring, 
dispensing or adhering errors) 
26 
(death, hospitalisation, 
permanent disability, need 






167 16.8 (30 days) Not reported Not reported 
Letrilliart 
(2001) 
4.0 0.4 (30 days) 59 









250 20.3 (30 days) Not reported Not reported 
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Table 4. Commonly implicated medicines and risk factors associated with MRH  
Study 
(year) 
Frequently implicated medicines in 
MRH (% of events) 




Analgesics (28.4%),  
Psychotropics & hypnotics (22.7%), 
Cardiovascular (20.6%) 
Not reported Not reported 
Ahmad 
(2014) 





Hypoglycaemic agents (13.9%) 
Age 
Gender 
Number of discharge diagnoses 
Individual diagnoses  
(Hypertension, Diabetes, Hyperlipidaemia, 
Ischaemic heart disease, Atrial fibrillation)  
Number of medicines* 
Drug-drug interactions 
Individual medicines/medicine class 
(ACE-I, Beta-blockers, Acetylsalicylic acid, 
Furosemide*, Statins, PPI, Potassium salts, 
Calcium-channel blockers, Warfarin*) 





Cardiovascular (55.7%),  
Opiates (9.5%)  













Individual medicines/medicine class 
(Warfarin*, Theophylline, 
Anticholinergics, Opioids, Antipsychotics, 












Anticoagulants (20%)  
Age* 
Gender 
Type of admission (planned/unplanned) 
Type of hospital (public/private) 




Cardiovascular (18.8%),  
Antibiotics (17.2%),  








Activities of daily living 
Cognitive status (MMSE)* 
Comorbidities 
Number of medicines 
Number of new discharge medicines* 
Medicines increase  
 
Female gender,  
Number of new discharge medicines,  
Lower MMSE score 
Abbreviations: Central Nervous System (CNS), Ischaemic Heart Disease (IHD), Mini-Mental State Examination (MMSE). *Statistically 
significant <0.05 
In three studies 
30,32,35
, for consistency, medicines were combined to calculate the proportion due to cardiovascular agents, using the 
WHO-ATC system 
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Figure 1. PRISMA flow diagram for included studies  
Supplemental Table S1. PRISMA Checklist 
Supplemental Table S2. Search strategy designed in Medline  
Supplemental Table S3. Data extraction form 





















Records identified through 
databases searching 



























Additional records identified 
through other source (n = 1) 
Records screened after duplicates removed  
(n = 584) 
Full-text articles assessed 
for eligibility 
(n = 31) 
Full-text articles excluded due to 
focus on medication issues other 
than MRH i.e. polypharmacy (n=3), 
inappropriate prescribing (n=3), 
medication discrepancies (n=3), 
patient knowledge (n=1), risk 
factors (n=1); average participant 
age <65 (n=6); hospital-based study 
(n=4); alternative analysis of 
included article (n=1); not specific 
to post-discharge period (n=2)  Studies included for 
systematic synthesis 
(n = 8) 
Records excluded due to 
irrelevance of title and abstract 
(n=338); review paper, 
interventional study, conference 
proceedings, research letters, 
protocol paper (n=79); article 
related to specific medicine or 
condition (n=67); study not 
investigating period post-hospital 
discharge (n=69) 
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Supplemental Table S1. PRISMA checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
3 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Table S1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
5, Fig 1 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
5 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
6, Fig 2 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
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Supplemental Table S1. PRISMA checklist 
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
6,Fig 2 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
6, Fig 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
6, Tables 
1&2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Fig 2 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
8 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  8, Table 
3 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Fig 2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
9-11 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
11 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  11 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
15 
 
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
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Supplementary Table S2. Search Strategy designed in Medline and 
adapted to other databases  
 
# Database Search term Results 
1 Medline exp *DRUG-RELATED SIDE 
EFFECTS AND ADVERSE 
REACTIONS/ep 
2837 
2 Medline (((drug* OR medication* OR 
medicine*) ADJ2 adverse) 
ADJ2 (effect* OR reaction* 
OR event* OR 
problem*)).ti,ab 
24362 
3 Medline ((drug* OR medication*) 




4 Medline (1 OR 2 OR 3) 38659 
5 Medline exp AGED/ 2665319 
6 Medline (elder* OR old OR older OR 
geriatr* OR gerontol* OR 
aging OR ageing OR senior* 
OR retiree* OR retired OR 
"late* life").ti,ab 
1486296 
7 Medline (5 OR 6) 3702870 
8 Medline *PATIENT DISCHARGE/ 10663 
9 Medline ((patient* OR hospital* OR 
clinic* OR unit*) ADJ3 
discharg*).ti,ab 
75713 
10 Medline (8 OR 9) 82693 
11 Medline (4 AND 7 AND 10) 232 
performed on 01 June 17 
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Table S3: Data extraction form 
 
Study Reference: 
Methods Study design:   
 
Study aim:  
 
 
Participants Number of participants:  
Mean age:    














































Outcomes Drop out/incomplete data: 
 




Incidence of MRH: 
 
Incidence by severity of MRH: 
 




Number of patients experiencing MRH: 
 
Number of events: 
 
 









































Adapted from Page AT, Clifford RM, Potter K, et al. The feasibility and effect of deprescribing 
in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin 
Pharmacol 2016;82:583-623 
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